RxDoctor Payments Data

Kent Hoffman, DO

Family Medicine · Maitland, FLNPI 1396711289

Payments from drug & device makers

$165,927in general payments, 2019–2025

Across 790 payments — averaging $210.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Braeburn Inc.$119K
  • Indivior Inc.$20K
  • Boehringer Ingelheim$10K
  • AbbVie$5K
  • Sandoz$2K
  • Orexo US, Inc.$2K
  • plus $8K from 47 others

What the payments were for

  • Consulting fees$4,4643%
  • Speaking & faculty fees$115,66374%
  • Travel & lodging$20,53213%
  • Food & beverage$15,47310%
  • Education$250%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$165,927 in reported general payments places this provider in the 95th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$124,572
Medicare patients
192
Services billed
1,616

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide31$39,908
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl202$37,422
SublocadeBuprenorphine11$21,968
FarxigaDapagliflozin Propanediol18$16,468
VyvanseLisdexamfetamine Dimesylate17$6,749
Jentadueto XrLinagliptin/Metformin Hcl14$5,716
Vilazodone Hcl13$3,069
Ezetimibe49$1,590
Rosuvastatin Calcium81$1,339
Oxycodone Hcl50$1,035
Pregabalin15$1,021
Testosterone Cypionate23$999
Pantoprazole Sodium49$933
Levothyroxine Sodium67$812
Buprenorphine Hcl42$766

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$873$39,90831 claims
Hikma Pharmaceuticals USABuprenorphine-Naloxone, Buprenorphine Hcl$20$38,188244 claims
Indivior Inc.Sublocade$19,983$21,96811 claims
AstraZenecaFarxiga$992$16,46818 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$135$6,74917 claims
Boehringer IngelheimJentadueto Xr$9,887$5,71614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Maitland

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →